drugset / Trial / NCT06275763

Optimal Medical Treatment of Difficult-to-treat Hypertension

NCT06275763

Phase 4 Unknown 2500 enrolled National Institute of Cardiology, Warsaw, Poland
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate best medical management to achieve the BP goals of ESC/ESH (120-129 / 70-79 mmHg) in HT patients who are \<65 years old and ineffectively treated (BP ≥ 130/80 mg) with 3 or more antihypertensive drugs

Timeline

Start
2023-10-20
Primary completion
2025-12-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified
Subject Eplerenone Unknown
Subject Indapamide Small molecule
Subject Olmesartan Other / unclassified
Subject Perindopril Small molecule
Subject Spironolactone Small molecule
Subject Torasemide Unknown
Subject hydrocholothiazide Unknown

Indications